- Conditions
- Cancer, Anxiety, Depressive Symptoms
- Interventions
- My Wellbeing Guide
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 751
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Interventions
- Attune™, Cerena™
- Device
- Lead sponsor
- Blue Note Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Glendale, California • Los Alamitos, California • Redlands, California + 10 more
- Conditions
- Uterine Cervical Neoplasms, Uterine Neoplasms, Ovarian Neoplasms, Urogenital Neoplasms, Fallopian Tube Neoplasms
- Interventions
- Guided Imagery With Audio Media
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Transfusion Related Acute Lung Injury
- Interventions
- Standard of Care
- Other
- Lead sponsor
- Cerus Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 12 more
- Conditions
- Bladder Cancer
- Interventions
- Cisplatin, Gemcitabine, Bevacizumab
- Drug
- Lead sponsor
- Christopher Sweeney, MBBS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 11
- States / cities
- Chicago, Illinois • Galesburg, Illinois • Evansville, Indiana + 7 more
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Interventions
- Quality-of-Life Assessment, Questionnaire Administration, Supportive Care
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Older Adults, Anxiety, Depression, Major Surgical Resection of a Thoracic Malignancy, Major Surgical Resection of an Abdominal Malignancy
- Interventions
- Behavioral Activation, Medication Optimization, Usual care resources
- Behavioral · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- DV281, Breath Actuated Nebulizer, DV281 (RP2D), Approved Anti-PD-1 Inhibitor
- Drug · Device
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- La Jolla, California • Santa Monica, California • Minneapolis, Minnesota + 3 more
- Conditions
- Advanced Solid Tumors
- Interventions
- mRNA-4106, Pembrolizumab, mRNA-4200
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Grand Rapids, Michigan • San Antonio, Texas + 1 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Axitinib, Avelumab, Pembrolizumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Small Cell
- Interventions
- GSK2879552
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Columbus, Ohio • Nashville, Tennessee
- Conditions
- Colorectal Cancer
- Interventions
- hydroxychloroquine
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 4
- States / cities
- Camden, New Jersey • Hamilton, New Jersey • New Brunswick, New Jersey + 1 more
- Conditions
- Rectal Cancer
- Interventions
- Capecitabine, Irinotecan, EUS, Neoadjuvant Chemotherapy, Preoperative Radiation, Surgery, Adjuvant Chemotherapy
- Drug · Procedure
- Lead sponsor
- Gabi Chiorean, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 9
- States / cities
- Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more
- Conditions
- Breast Cancer
- Interventions
- everolimus, abraxane
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 3
- States / cities
- Camden, New Jersey • Hamilton, New Jersey • New Brunswick, New Jersey
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Standard Leukemia Care, Palliative Care
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Durham, North Carolina • Columbus, Ohio + 1 more
- Conditions
- Leukemia
- Interventions
- topotecan hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 20 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 22 more
- Conditions
- Solid Tumor, Malignant Lymphoma, Tumor
- Interventions
- ARQ 092
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Miami, Florida + 3 more
- Conditions
- Colorectal Cancer
- Interventions
- CHW/P Navigator Support, Social Services Resource List
- Behavioral · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Prostate Cancer, Kidney Cancer, Bladder Cancer
- Interventions
- Text or email message
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Evanston, Illinois
- Conditions
- Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Non-Hodgkin Lymphoma
- Interventions
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 811 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 119 more
- Conditions
- Lung Cancer
- Interventions
- LuCA Behavioral Intervention
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer, Triple Negative Breast Cancer
- Interventions
- MM-151, MM-151 + irinotecan
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Lafayette, Indiana • Buffalo, New York + 1 more
- Conditions
- Granulocyte Colony-Stimulating Factor, Chemotherapy-induced Neutropenia, Chemotherapy-Induced Febrile Neutropenia, Pediatric Cancer
- Interventions
- Granulocyte Colony-Stimulating Factor
- Drug
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi